Dasabuvir is an inhibitor of UGT1A1 and P-glycoprotein (P-gp). It is metabolized by CYP2C8 and it is a substrate for P-glycoprotein (P-gp).
Ombitasvir is an inhibitor of UGT1A1, and it is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Paritaprevir is an inhibitor of UGT1A1, and it is an inhibitor of the following transporters: OATP1B1 and OATP1B3. It is metabolized by CYP3A4 and it is a substrate for P-glycoprotein (P-gp).
Ritonavir is an inhibitor of CYP3A4 and P-glycoprotein (P-gp). It is metabolized by CYP3A and it is a substrate for P-glycoprotein (P-gp).
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP52 Dasabuvir, ombitasvir, paritaprevir and ritonavir
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Dasabuvir/ Ombitasvir/ Paritaprevir/ Ritonavir
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG01633 CYP3A/CYP3A4 substrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG02887 UGT1A1 inhibitor
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
Transporter substrate
DG01665 ABCB1 substrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG01913 ABCG2 substrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG02856 SLCO1B1 substrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG02932 SLCO1B3 substrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
Transporter inhibitor
DG02862 ABCG2 inhibitor
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG02865 SLCO1B1 inhibitor
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
DG02907 SLCO1B3 inhibitor
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HCV NS3/4A inhibitor
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10582
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10582
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10582
Drug transporters
D10582
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D10582